Allarity Therapeutics (ALLR) Other Non Operating Income (2020 - 2026)
Allarity Therapeutics' (ALLR) quarterly Other Non Operating Income came in at $4000.0 in Q1 2026, down 97.1% YoY from $138000.0 in Q1 2025, and up 100.73% on a QoQ basis from -$551000.0 in Q4 2025.
Allarity Therapeutics (ALLR) Other Non Operating Income (2020 - 2026) Analysis & Trends
Allarity Therapeutics (ALLR) has 7 years of Other Non Operating Income data on file, last reported at $4000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 97.1% year-over-year to $4000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $623000.0 (up 515.33% YoY) and the FY2025 annual result came in at $757000.0, up 457.08% from the prior year.
- Other Non Operating Income climbed to $4000.0 in Q1 2026, from -$551000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $1.6 million in Q2 2025 to a low of -$14.2 million in Q4 2022.
- A 5-year average of -$865882.4 and a median of -$128000.0 in 2024 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2024 — Other Non Operating Income slumped 2107.14% — and 2025, when it soared 1340.62%.
- Tracing ALLR's Other Non Operating Income over 5 years: stood at -$14.2 million in 2022, then jumped by 100.1% to $14000.0 in 2023, then tumbled by 2107.14% to -$281000.0 in 2024, then tumbled by 96.09% to -$551000.0 in 2025, then surged by 100.73% to $4000.0 in 2026.
- The last three Other Non Operating Income figures came in at $4000.0 (Q1 2026), -$551000.0 (Q4 2025), and -$418000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Allarity Therapeutics | 22.75 Mn | 22.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,000.00 |
| Dec 31, 2025 | -551,000.00 |
| Sep 30, 2025 | -418,000.00 |
| Jun 30, 2025 | 1.59 Mn |
| Mar 31, 2025 | 138,000.00 |
| Dec 31, 2024 | -281,000.00 |
| Sep 30, 2024 | 121,000.00 |
| Jun 30, 2024 | -128,000.00 |
| Mar 31, 2024 | 76,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Sep 30, 2023 | -156,000.00 |
| Jun 30, 2023 | -26,000.00 |
| Mar 31, 2023 | 95,000.00 |
| Dec 31, 2022 | -14.19 Mn |
| Sep 30, 2022 | -470,000.00 |
| Jun 30, 2022 | -269,000.00 |
| Mar 31, 2022 | -269,000.00 |
| Dec 31, 2021 | -1.86 Mn |
| Sep 30, 2021 | 1.79 Mn |
| Jun 30, 2021 | -990,000.00 |